癌症治疗后甲状腺功能减退与生存结局的关联
该研究为密歇根大学2006至2023年的回顾性队列研究，纳入9909例接受ICI、TKI或放疗且既往无甲状腺疾病或恶性肿瘤的成人患者，用时间依赖Cox模型分析。结果显示，治疗诱导的甲减与总生存和无癌特异性生存改善相关，ICI和放疗后显著，TKI后不显著；脑/中枢神经系统、唇/口腔/咽、肺/支气管癌有获益，结肠癌死亡率更高。
要点
- 治疗诱导甲减与总体及肿瘤特异性生存改善相关，或可作疗效预后生物标志物。
- ICI和放疗后甲减与生存改善显著相关，TKI后未观察到显著关联。
- 部位差异明显：脑/中枢神经系统、肺/支气管癌有获益，结肠癌死亡率升高。
核心结论
- 治疗诱导的甲减与总体生存（HR=0.86 [0.79-0.93]，p<0.001）和肿瘤特异性生存（HR=0.76 [0.70-0.84]，p<0.001）改善相关。
- ICI和放疗后甲减与生存改善相关，提示其可能作为治疗获益的预后生物标志物。
研究设计与样本
- 密歇根大学2006至2023年去标识电子健康记录回顾性队列研究，纳入9909例成人患者（≥18岁），共57,772人年，中位随访4.64年。
- 纳入接受ICI、TKI或放疗且既往无甲状腺疾病或恶性肿瘤者，甲减由机构实验室标准或启动甲状腺激素定义。
- 采用时间依赖Cox模型估计风险比（HR）及95%置信区间，校正人口学、临床和生活方式因素，并按治疗类别和肿瘤部位分层分析。
主要发现
- 9909例中2177例（22.0%）发生甲减，中位发生时间5.04个月。
- ICI后甲减：总体HR=0.75 [0.61-0.92]，p=0.014；肿瘤特异性HR=0.75 [0.66-0.94]，p=0.012。
- 放疗后甲减：总体HR=0.88 [0.81-0.96]，p=0.011；肿瘤特异性HR=0.76 [0.68-0.84]，p<0.001；TKI后未观察到显著关联。
- 部位特异性：脑/中枢神经系统HR=0.39 [0.26-0.61]，p<0.001；唇/口腔/咽HR=0.77 [0.61-0.97]，p=0.032；肺/支气管HR=0.80 [0.66-0.97]，p=0.034；结肠癌死亡率更高HR=1.82 [1.10-3.02]，p=0.021。
- 敏感性分析结果一致。
临床怎么用
- 对接受ICI或放疗的肿瘤患者，出现治疗诱导甲减可能提示生存获益，可作为预后评估参考。
- 不同肿瘤部位关联方向不一，结肠癌患者出现甲减时需警惕更高死亡风险。
- 甲减的诊断与甲状腺激素启动应遵循机构实验室标准，并纳入随访监测。
局限性
- 为单中心回顾性队列研究，可能存在残余混杂。
- 甲减定义依赖机构实验室标准或激素启动，可能存在错分。
- TKI亚组及部分肿瘤部位样本量有限，结果需外推验证。
以上解读依据论文摘要（全文未开放获取或许可不允许翻译转载）。
原文
BACKGROUND: Hypothyroidism is a recognized adverse effect of cancer therapies such as immune checkpoint inhibitors (ICI), tyrosine kinase inhibitors (TKI), and radiotherapy. Although proposed as an indicator of treatment response, its prognostic significance across cancer types and therapies remains underexplored. This study evaluated survival outcomes associated with treatment-induced hypothyroidism. METHODS: We conducted a retrospective cohort study using de-identified electronic health record data from the University of Michigan (2006-2023). Adults (≥18 years) receiving ICIs, TKIs, or radiotherapy, without prior thyroid disease or malignancy, were included. We defined hypothyroidism by institutional laboratory criteria or thyroid hormone initiation. Time-dependent Cox models estimated hazard ratios (HRs) and 95% confidence intervals for overall and cancer-specific survival, adjusting for demographic, clinical, and lifestyle factors. Analyses were stratified by treatment class and cancer sites; sensitivity analyses assessed robustness. RESULTS: Among 9909 patients (57,772 person-years; median follow-up 4.64 years), 2177 (22.0%) developed hypothyroidism (median onset time: 5.04 months). Treatment-induced hypothyroidism was associated with improved overall (HR = 0.86 [0.79-0.93], p < 0.001) and cancer-specific survival (HR = 0.76 [0.70-0.84], p < 0.001). Stratified analyses showed significant survival benefits with hypothyroidism following ICI (overall HR = 0.75 [0.61-0.92], p = 0.014; cancer-specific HR = 0.75 [0.66-0.94], p = 0.012) and radiotherapy (overall HR = 0.88 [0.81-0.96], p = 0.011; cancer-specific HR = 0.76 [0.68-0.84], p < 0.001), but not for TKI. Site-specific survival benefits were observed in brain/central nervous system (HR = 0.39 [0.26-0.61], p < 0.001), lip/oral cavity/pharyngeal (HR = 0.77 [0.61-0.97], p = 0.032), and lung/bronchus cancers (HR = 0.80 [0.66-0.97], p = 0.034) but higher mortality in colon cancer (HR = 1.82 [1.10-3.02], p = 0.021). Results were consistent across sensitivity analyses. CONCLUSIONS: Hypothyroidism after ICI and radiotherapy was associated with improved survival, supporting its potential as a prognostic biomarker of therapeutic benefit. Future studies should investigate the underlying mechanisms and clinical implications.
引用
- Momo HD, Haymart MR, Shi X, et al. Survival Outcomes Associated with Hypothyroidism Following Cancer Therapies. Thyroid. 2026. PMID: 42104919. doi:10.1177/10507256261449473
供执业医师工作参考，不替代临床判断；数值与分级以指南原文为准。